Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the University of Oxford have developed a mindfulness training specifically for people with irritable bowel syndrome.

We are interested in finding out if this training is effective at reducing the symptoms of IBS and how the training achieves its effects. Interested? Please keep on reading to find out what is involved for you:

What is involved?

  • A six week mindfulness course
  • Regular study assessments

About the mindfulness course

Mindfulness for IBS is a new mindfulness course specifically for people with irritable bowel syndrome. The course consists of 6 x 2 hour group sessions over 6-7 weeks. During the course you will develop awareness of your mind and body through the cultivation of mindful awareness. The aim of the course is to reduce the symptoms of IBS and help you increase your mental and physical wellbeing.

Study Participation: The course is provided at no cost to you as participant

About the assessments

You will be asked to do 3 assessment visits at the Department of Experimental Psychology and 4-8 online questionnaires before, during and after the course. Each assessment visit takes 1-1.5 hours. Each questionnaire takes 30-45 minutes.

Are you eligible? 

  • Do you have a diagnosis of IBS?
  • Are you interested in trying mindfulness as a treatment for IBS?
  • Are you a woman between 18 and 65 years of age?

Location

Course: Oxford Mindfulness Centre, Oxford University

Assessments: Department of Experimental Psychology, Oxford University

Dates and Registration

To find out more about the study, when the courses take place and to register, please contact Julia Henrich via email Julia.Henrich@psy.ox.ac.uk.

You can also sign up online.

 

NHS REC Reference: REC: South Central – Oxford A, 15/SC/0618

Similar stories

New form of gift wrap drives male reproductive success

General Research

A study from the Department of Physiology, Anatomy and Genetics (DPAG) has identified a new communication mechanism that ensures the transfer of a complex mix of signals and nutrients required for successful reproduction between males and females.

PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19

Coronavirus COVID-19 General Research

In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.

Early animal studies yield promising results for new potential COVID-19 vaccine

Coronavirus COVID-19 General Research

Studies carried out in the MRC Human Immunology Unit (MRC HIU) in collaboration with the Pirbright Institute have shown that a new potential vaccine against COVID-19, named RBD-SpyVLP, produces a strong antibody response in mice and pigs, providing vital information for the further development of the vaccine. Although this type of vaccine is not a competitor for the first wave of vaccines, it is hoped that it will be useful as a standalone vaccine or as a booster for individuals primed with a different COVID-19 vaccine.

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.